Molecule to Market: Inside the outsourcing space

Poacher turned gamekeeper, turned hybrid

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Peter Bigelow President at xCell Strategic Consulting.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Peter, covering:

• The transition from being on the big pharma sponsor side at Pfizer to being head of one of the world’s biggest CDMOs.
• The challenging of adding a development capability to well-oiled manufacturing infrastructure and way of working.
• They key buying criteria emerging pharma considers when choose a CDMO.
• Increasing consolidation and fragmentation in today’s outsourcing sector due to continued market growth and the explosion of new technologies.

Pete is a very well respect industry leader having spent over 25 years in the global pharmaceutical manufacturing space. He was at Wyeth and then Pfizer for the best part of 15 years before becoming the interim CEO and President of North American operations at Patheon. He since moved into management consulting before establishing his own firm called xCell in 2014.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

The humble leader

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Steve Ferguson, Chief Executive Officer at Medix Biochemica. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Steve, covering:

• The positive and negative impact of Covid-19 on the diagnostic sector. And the need for more spend on diagnostic sector moving forward.
• How his humble and grounded upbringing gave him an early respect for the strength of women and gender equality.
• Simply the importance of having fun, enjoying yourself and making a difference at work. Otherwise, what’s the point?
• The importance of creating visibility in a fragmented segment of the outsourcing space and then overlaying relevance to the buyer.

With around 25 years’ experience in the life science sector, Steve has worked for the likes of Lundbeck and Thermo Fisher before joining Medix Biochemica at the CEO. He is an expert in the pharma and diagnostic space and well-respected industry leader.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

The understated, elite vaccine scientist

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Archie Lovatt Life Sciences Biosafety Scientific Director at SGS.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Archie, covering:

• Being motivated by saving lives and seeing your contribution make a real impact on the world. Following your heart and not chasing the money.
• Seeing Covid-19 drugs developed in a parallel rather than sequential way, helping accelerate the process while not compromising on safety.
• Being acquired by SGS yet maintaining the entrepreneurial spirit to explore and innovate.
• The long term value to patients of now having more platform technologies and a greater operational infrastructure to deal with disease areas.

Archie is a vaccine, gene and cell therapy biosafety testing expert. He graduated with a PhD in molecular microbiology and has been in the industry for the best part of 30 years. During this time, he founded a CRO called Vitrology, which was then acquired by SGS in 2012 and has since served on the board as Scientific Operations Director. He was also voted into the top 100 most influential people in human medicine development and manufacture.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

Creating a healthy culture

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jeff Dill, CEO at Vynamic.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jeff, covering:·    

• How to create, document, grow and internationally scale an incredible business culture.
• The shift towards greater industry collaboration as an important step for quicker drug approvals in the future.
• Servant leadership philosophy - to listen, be empathetic and enable.
• The drive and transparency needed to create a more diverse and inclusive workforce.

Jeff boasts over 20 years’ experience in the healthcare consulting world. Previously at Accenture, Jeff joined healthcare industry management consulting firm Vynamic in 2005, he has been there ever since and is now the CEO.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

40 at 40

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Raman Sehgal Founder & Global President of ramarketing & usual host of the Molecule to Market podcast.
 
Raman has 20+ years of marketing and life science industry experience. Starting his career and setting up his business in the UK, Raman now resides stateside after relocating to the US to open an office in Boston. Raman previously worked for The Specials Laboratory and SCM Pharma before setting up and leading ramarketing globally.
 
In this special 40th episode, Raman is handing over the microphone and questions to his friend and returning guest Dan Stanton, Editor at Bioprocess International and Managing Editor at Xconomy. Your guest host is turning the tables and using his journalistic experience to present the show.

In this episode Dan and Raman chat about the evolution of ramarketing, going global and the cultural differences and risk adversity between UK and US business styles. They also discuss how a people-centric approach enabled ramarketing to flourish and offer up 7 timeless tips for handling PR. You will also hear how Raman’s early childhood experiences instilled his strong work ethic and took him from being a playground confectionary supplier to become a successful entrepreneur and global agency owner working across the life sciences and pharma sector.

Hear Raman discuss:
●     His early life and where his business ethic came from.
●     How his marketing expertise led him to become an ‘accidental agency owner’.
●     Why his playground entrepreneurial spirit defined him as a businessperson.
●     The value of developing a people-centric business & why you shouldn’t burn bridges in business.
●     7 timeless tips for working with journalists.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

From Pfizer to CDMO start-up

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Gerry Cox, Founder and Chief Operating Officer at Velesco Pharmaceutical Services.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Gerry, covering:    

• The transition from two decades in Big Pharma to the entrepreneurial world of running a CDMO.
• Becoming known as the ‘lab down the hall’ for many clients with products in the clinical phase of development.
• The value of talking to people, networking and not being intimidated when starting out your own business.
• Consistently keeping your operational house in order in the face of increasing market demand.

Raman has taken great pleasure in getting to know fellow Bostonian Gerry, since moving to the states. An accountant by trade, Gerry worked for Pfizer for eighteen years in corporate and research & development roles, both globally and onsite. Since founding Velesco back in 2007, he has led the steady growth of the company’s operations and its most recent expansions. A phenomenal networker, Gerry enjoys connecting people and communicating with people within the sector.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Expanding drug dosage possibilities…

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Megan Greth, Director of Marketing & Business Development and Tadgh Prendeville, General Manager at ARx LLC.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Megan and Tadgh, covering:

•     The developments & demands for new transdermal drug products and oral thin films as a more patient centric drug delivery platform.
•     How the focus on Covid-19 related vaccines directly impacted the drug product supply chain.
•     ‘Lean’ observations on the speed (or not) of the pharma manufacturing sector.
•     Reflections on the career ‘ride’ and the sectors core focus – making drugs for sick people.
•     Learning to not sweat the small stuff and to ride out any storms.
•     Chicken-and-egg capacity and capability challenges for CDMO investment as clients edge closer to commercial approval.

 

Who are the ARx duo?

With a Bachelor of Science, Megan has been in the sector for around 15 years. She is now responsible for market assessment and strategic selection of new projects that will benefit from ARx’s drug delivery technologies. Whilst Tadgh has a background in bioengineering and has worked in manufacturing and operations and as a lean consultant, before progressing to his current role as head of ARx.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

From Teesside Uni to global leader

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jarlath Keating President & CEO at ABL Inc.

Jarlath has over 25 years of global life science industry experience. Starting his career in the UK in the early 90’s before transitioning to the US in 2009. During this time, Jarlath worked for HyClone and Lonza Biologics. He served as the Vice President of Global Commercial Operations for MilliporeSigma’s Process Solutions Services division, leading the BioReliance® biological safety testing and biomanufacturing divisions. He now leads ABL, globally.

Your host, Raman Sehgal, leads a conversation on the pharmaceutical and biotechnology supply chain, transitioning from ‘shop floor’ to CEO, and the impact of COVID-19 from a manufacturing point of view. Hear Jarlath’s thoughts on:

•     The importance of leaders building knowledge across the whole business.
•     Understanding the jigsaw - your success is dependent upon the success of your colleagues.
•     Taking opportunities, leaning into risk, and backing yourself through belief and hard work.
•     The evolution of the gene therapy and cell therapy space, and the operational challenges it brings.
•     How contract service providers must anticipate rather than react to future pandemics and new areas of development.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

The accidental CDMO

In this episode of Molecule to Market, your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest Richard Johnson, Founding Director of Upperton Pharma Solutions. With more than 25 years of experience in the industry, Richard is a founding director of two, successful pharmaceutical companies. He has authored 30 scientific publications and is the named-inventor on more than 20 patents. His research experience spans a broad range of scientific disciplines particularly in the field of pharmaceutical spray drying and drug delivery. This knowledge has been used in the successful development of a number of pharmaceutical products from early research to testing on patients.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Richard, covering:

• Greater collaboration and alliance between smaller, specialist early phase contract service providers as a way to compete against the global one-stop-shops.
• Increased demand for nasal and pulmonary delivery as a result oft the pandemic. And why Richard was not surprised to see a Covid-19 vaccine developed so quickly.
• The contrast of founding a steady 20-year growth business and the another that exited in just five years.
• The increasing demand and application for spray drying technology to solve modern pharmaceutical development challenges.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

 

The passionate problem solver

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Robert Lee Ph.D., President at the CDMO Division of Lubrizol Life Science Health (LLS). Rob has over 30 years’ experience in the pharmaceutical R&D space and his areas of expertise include drug delivery, formulation development, analytical sciences and sterile manufacturing. With a Ph.D. in Physical Bioorganic Chemistry, Rob has published more than three dozen articles and five book chapters. Plus, he holds 11 issued patents and 15 provisional or PCT patent applications. He has worked for some major companies in the sector and was appointed President of the CDMO Division of LLS after 10 years with the business.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Rob Lee, covering the new paradigm for drug development and manufacturing after the speed to market achieved by the COVID-19 vaccines. Rob then explains how patient-friendly dosage forms will continue to play an increasingly important role in the future. Rob also gives us an idea of the types of molecules and projects coming through the pipeline at the moment and what is in store for LLS. Lastly Rob shares what it’s been like to transition from a scientist to a leader while keeping science at the heart of everything he does. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.